The diagnostic value of normalized ADC using spleen as reference organ in assessment liver fibrosis

Mai A. Mostafa, Omnia Kamal, Aya Yassin*, Mona A. Nagi, Osama A. Ahmed and Hagar A. Ahmed

Abstract

Background: To investigate the value of liver ADC normalization using spleen as a reference organ in liver fibrosis assessment compared to Fibroscan.

A total of 60 participants were included, 30 HCV positive patients and 30 in control group. We calculated mean spleen apparent diffusion coefficient (ADC), liver mean ADC, and normalized liver ADC (defined as the ratio of liver ADC to spleen ADC) which were compared between cirrhotic patients and the control group. Data was analyzed, and ROC was used to evaluate the performance of nADC.

Results: No significant difference between spleen ADC values of patient and control groups or in-between different fibrosis stages. A negative correlation between liver ADC and nADC values with increasing fibrosis stages. We also found that the mean liver ADC and nADC value in patients with hepatic fibrosis were significantly lower than that of control group ($1.53 \times 10^{-3}$ mm$^2$/s vs $1.65 \times 10^{-3}$ mm$^2$/s). After analysis with ROC, nADC shows higher diagnostic performance compared to liver ADC. nADC area under the curve (AUC) was 0.878 for detection of stage $\geq$ F2 with sensitivity and specificity of 87% and 80% respectively while ADC AUC was 0.548 with sensitivity and specificity of 62% and 72% respectively ($p = 0.021$); $\geq$ F3 AUC of nADC was 0.891 with sensitivity and specificity of 88.7% and 80% respectively while ADC AUC is 0.603 with sensitivity and specificity of 72% and 72% respectively ($p = 0.023$), and F4 stage nADC AUC was 0.879 for with sensitivity and specificity of 90% and 80% respectively, while ADC AUC was 0.648 with sensitivity and specificity of 80% and 72% respectively ($p = 0.054$).

Conclusion: Normalized liver ADC using the spleen as reference organs increases the diagnostic performance of MR in evaluation liver fibrosis compared to ADC alone.

Keywords: MRI DWI, Hepatitis C virus, Liver fibrosis, Liver cirrhosis, Fibroscan

Background

HCV (hepatitis C virus) causes liver cell injury which may be acute or chronic. In the chronic stage, the injury by fibrous tissue accumulates in extracellular space. Hepatitis C viral infection is the most common cause of liver fibrosis in Egypt [1].

Liver fibrosis plays a role in other liver lesions pathogenesis as HCC (hepatocellular carcinoma), portal hypertension, and cirrhosis [2].

The assessment of liver fibrosis in patients with viral hepatitis is essential to follow-up on the disease progression as well as to detect patients who need antiviral treatment [3].

Liver biopsy is the gold standard for evaluating changes in fibrosis. It is considered a safe procedure but still invasive and had some contradictions and complications [4]. So, we needed a non-invasive procedure that offers a safe, fast, and reproducible way for assessing hepatic fibrosis to monitor the response of treatment [5].
Non-invasive radiological methods that were investigated are Fibroscan, (MRE) magnetic resonance elastography, diffusion-weighted imaging (DWI), perfusion-weighted imaging, and MR spectroscopy [6].

Fibroscan is a non-invasive method for evaluating liver fibrosis in chronic liver injury. However, it has some limitations in different situations as in obese patients, ascites, and narrow intercostal spaces [7].

Diffusion-weighted imaging (DWI) is also a promising non-invasive method as it assesses tissue diffusivity which is being low in HCV patients with fibrosis due to the accumulation of fibrous tissue within the extracellular matrix. Multiple studies confirmed this hypothesis as patients with livers fibrosis had low ADC compared to normal individuals [8].

However, other studies revealed using different b values could lead to variable ADC measurements as well as breathing methods like breath-hold, free-breathing, or respiratory triggered techniques, which can affect ADC quantification [9].

To reduce the variability of ADC values, researchers suggested that normalization of ADC using a reference organ that remains relatively constant across patients or systems could be the solution to this problem. Multiple studies showed that normalized ADC (using the spleen) as reference organ improves the diagnostic performance in assessing liver fibrosis than using ADC alone. The spleen may be an ideal reference organ because it maintains a relatively stable ADC even in the setting of liver disease [10].

**Methods**

**Subjects**

A total of 30 HCV patients were included in the study after obtaining approval from the local ethics committee and informed consent from the patients. The clinical diagnosis of all the patients was established based on the patient’s clinical symptoms, physical findings, and laboratory tests. The ADC values of the patients were compared with their normal counterparts. The control group for this study consisted of another 30 patients who underwent abdominal MRI owing to pancreatic, adrenal, and renal pathology but who had no known hepatic disorders.

**Technique of Fibroscan**

All patients were examined by TE, transient elastography (Fibroscan®502; Echosens, Paris, France). Measurements of liver stiffness were performed by 5 years experienced internist on the right lobe of the liver through intercostal spaces in correspondence to the mid-axillary line, while patients are lying in the supine position with the right arm in maximal abduction. A median of 12 valid readings was calculated. The results were expressed in kilopascals (kPa) and interpreted as follows: F0 (control group), < 5 kPa; F1, 5–7 kPa; F2, 7–9.5 kPa; F3, 9.5–12.5 kPa; and F4, > 12.5 kPa.

**MRI examination**

1.5T machine (Achieva, Philips medical system, Eindhoven, Netherlands), using Torso phased-array coil to acquire DWI of liver and spleen, three b values were taken of 0, 400, 800 mm²/s, then on FujifiLN, synapse 3D, and V4.4EU. We calculated mean spleen apparent diffusion coefficient (ADC), liver mean ADC, and normalized liver ADC (defined as the ratio of liver ADC to spleen ADC) which were compared between cirrhotic patients and patients in the control group.

The examination protocol included DWI performed using single-shot echo-planar imaging (EPI) fat suppressed sequence in the axial plane, during a single end-expiratory breath-hold, using b values of 0, 400, and 800 s/mm² using the following parameters (Table 1).

**Quantitative image analysis**

A single radiologist with 3 years of experience in body MR imaging drew regions of interest (ROIs) on DWI, and they were identically positioned on corresponding ADC maps by applying the copy and paste functions of the PACS system at the same points measured by the Fibroscan. The surface area of the ROIs was 20 mm². Five ROIs inserted on the liver one at the left lobe, one at the caudate lobe, and 3 separate points in the right lobe as follows: one at the anterior segment and two at the posterior segment, one at segment 6, and other at segment 7. The mean hepatic ADC value was calculated by taking the mean of the total of five ADC measurements obtained. For the spleen ADC measurements, a circular ROI of approximately 20 mm² was used. The measurements were taken from parenchyma areas at

| Parameter | Value |
|-----------|-------|
| TR (ms)   | 1,600–3,400 |
| TE (ms)   | 80 |
| SNR       | 0 |
| NEX       | 2 |
| ST (mm)   | 3 |
| Gap (mm)  | 0 |
| FOV (cm)  | 421 |
| Matrix    | Up to 256 x 256 |
least 1 cm away from the capsule and not crossing major vascular structures as far as possible. Three ROIs were drawn as one each from the inferior pole, the interpolar section, and the superior pole. The mean spleen ADC value was calculated from the mean of the three measurements (Fig. 2). Then, normalized ADC value was calculated by dividing mean liver ADC over mean spleen ADC.

Data management and analysis
The collected data was revised, coded, tabulated, and introduced to a PC using Statistical package for Social Science (SPSS 20). Data was presented, and suitable analysis was done according to the type of data obtained for each parameter.

Analytical statistics
One tailed $t$-test is to compare between control and patients’ groups.

Mann-Whitney test ($U$ test) was used to assess the statistical significance of the difference of a non-parametric variable between two study groups.

Correlation analysis (using Spearman’s method) is to assess the strength of association between two quantitative variables. The correlation coefficient denoted symbolically $r$, $r^*$ defines the strength (magnitude) and direction (positive or negative) of the linear relationship between two variables. Liver ADCs, spleen ADCs, and normalized liver ADCs were correlated with fibrosis scores.

The ROC curve (receiver operating characteristic) provides a useful way to evaluate the sensitivity and specificity for quantitative diagnostic measures that categorize cases into one of two groups.

Differences in ADC values were statistically significant when $p < 0.05$.

Results
Total participants are 60 in this study: 30 controls (19 females and 11 males of mean age 34 ± 10 years) and 30 patients: 16 females and 14 males with mean age 47 ± 11, F1 (n = 6), F2 (n = 6), F3 (n = 8), and F4 (n = 10).

There was significant difference between the mean liver ADC value of the liver in the control group ($1.65 \times 10^{-3}$ mm$^2$/s) compared to patients ($1.53 \times 10^{-3}$ mm$^2$/s with $p = 0.04$). As well as the nADC, there was significant difference between cases (nADC = 1.39) and controls (nADC = 1.87 with $p = 0.006$) (Table 2).

Correlations between fibrosis stage, liver ADC, and normalized liver ADC

- Mean ADC of the liver and nADC value show negative correlation with increasing fibrosis stages (Table 3 and Fig. 1), but there were some overlaps in different stages of fibrosis.

Correlations between fibrosis stage and spleen ADC
There was no significant difference between mean spleen ADC values among participants with different fibrosis stages (Fig. 2).

Correlations between liver ADC, normalized ADC, and spleen ADC

- There was no significant correlation between mean liver ADC or nADC and mean spleen ADC in the 30 cases (Fig. 3).

Differentiating fibrosis stages using ADC and nADC
Mean liver ADC could not differentiate each individual stages of fibrosis except between F0 versus F4.

- nADC has significant differences between F0 and F2, F3, and F4 (Table 4).

Diagnostic performance of ADC and nADC using of receiver operating characteristic (ROC) curve analysis for each stage
According to ROC analysis, nADC exhibited a good diagnostic performance for each stage of fibrosis, with AUCs higher than those of ADC.

The optimal cut-off values of nADC liver and ADC for each fibrosis stages are shown in Table 5.

### Table 2 Mean liver and spleen ADC and nADC in control and patients’ groups

|                                | Control group (No=30) | Patient group (No=30) | t-test       | $P$-value | Sig |
|--------------------------------|-----------------------|-----------------------|--------------|-----------|-----|
| Mean ADC liver                 | 1.65±0.9              | 1.53±0.41             | 1.72778      | 0.0468*   | S   |
| Range                          | 0.9-2.3               | 0.9-2                 |              |           |     |
| Mean ADC spleen                | 0.85±1.61             | 1±0.33                | 1.29422      | 0.242     | NS  |
| Range                          | 0.6-1.8               | 0.8-1.7               |              |           |     |
| Normalized ADC                 | 1.87±0.50             | 1.39±0.49             | -6.12057     | 0.001*    | S   |
| Range                          | 1.1-3                 | 0.94-2                |              |           |     |

One tailed T-Test, $P*$=significant
Table 3 Negative correlation was noted between liver ADC value as well as nADC with increasing fibrosis stage

| Fibrosis stage | NO | Mean Liver ADC ($\times 10^{-3}$ mm$^2$/s) | Mean Spleen ADC($\times 10^{-3}$ mm$^2$/s) | Mean nADC |
|----------------|----|--------------------------------|--------------------------------|-----------|
| Control group F0 | 30 | 1.65                          | 0.87                             | 1.8       |
| F1              | 6  | 1.59                          | 1.1                              | 1.45      |
| F2              | 6  | 1.55                          | 1.13                             | 1.42      |
| F3              | 8  | 1.5                           | 1                                | 1.4       |
| F4              | 10 | 1.48                          | 1                                | 1.38      |

Fig. 1a, b shows negative correlation between mean liver ADC of control group and different fibrosis stages groups. (Spearman’s rank correlation coefficient $r_s = -0.6$, 95% CI: -0.446–0.015, $p = 0.0374$), also negative correlation between nADC of control group and different liver fibrosis stages groups. (Spearman’s rank correlation coefficient $r_s = -0.82$, 95% CI: -0.634–0.285, $p < 0.001$)
Fig. 2 Shows no significant correlation between mean spleen ADC in different fibrosis stages. (Spearman’s rank correlation coefficient \( r_s = 0.105 \); 95% CI: \(-0.153\)–\(0.350\), \( p = 0.866 \)).

Fig. 3 a, b shows no significant correlation between liver and mean spleen ADC (\( n = 30 \)) of patients with different stages of fibrosis (Spearman’s rank correlation coefficient \( r_s = 0.00335 \); 95% CI: \(-0.357\)–\(0.363\), \( p = 0.9 \)), also no significant correlation between nADC and mean spleen ADC (Spearman’s rank correlation coefficient \( r_s = -0.225 \); 95% CI: \(-0.538\)–\(0.125\), \( p = 0.1743 \)). (Image quality adjusted)
Comparing diagnostic performance of liver apparent diffusion coefficient (ADC) versus normalized liver ADC for detection of fibrosis stages ≥ F2, ≥ F3, and F4 using ROC curves analysis

According to ROC curves analysis, nADC liver exhibited a good diagnostic performance for moderate (> F2) and severe (> F3) fibrosis stages compared to ADC as they show a larger area under the curve (AUCs) (Table 6, Fig. 4). There is a statistically significant difference between the area under the receiver operating characteristic curve (AUC) of nADC liver vs ADC liver except for the F4 stage; our results were as follows (Figs. 5, 6, 7):

1. Fibrosis stage ≥ F2, 0.878 vs 0.548 (p = 0.021);
2. Fibrosis stage ≥ F3, 0.891 vs 0.603 (p = 0.023); and
3. Fibrosis stage F4, 0.879 vs 0.648 (p = 0.054).

In our study, normalized ADC was done on a single patient with moderate ascites, but he was excluded as Fibroscan results are not accurate in cases with ascites. It was classified as F4 by Fibroscan while mean liver ADC value = 1.5 and mean spleen ADC = 1.07 and nADC = 1.4 (Fig. 8).

Discussion

Hepatitis C virus (HCV) is the main agent of post-transfusion chronic hepatitis and liver fibrosis [11]. The highest incidence of HCV infection in the world is in Egypt [12], which makes a need for different laboratory and radiological methods to assess liver injury [13].

In the last few years, Fibroscan was considered as a fast, safe, and reproducible procedure to assess liver stiffness to predict liver fibrosis stage [14–16].

However, Fibroscan cannot be used in obese patients, ascites, and narrow intercostal spaces [17].

Diffusion-weighted imaging enables qualitative and quantitative assessment of tissue diffusivity. Random motion of water molecules in the liver can be quantified by calculation of the apparent diffusion coefficient (ADC). The ADC of livers with moderate or advanced fibrosis and cirrhosis has been reported to be lower than that of normal livers or livers with mild fibrosis across multiple studies [18].

DWI is a crucial sequence in the MR abdomen, but the lack of standardization of DWI acquisition techniques is a major limitation of more broad and uniform use of ADC measurements as a quantitative biomarker. The variability in reported ADC values is further complicated by the use of different b values and acquisition methods based on breath-hold, free-breathing, or respiratory triggered techniques, which can affect ADC quantification and that should have influenced all of the abdominal organs scanned, including not only the liver, but also the spleen, pancreas, kidney, and paraspinal muscle. So, in our study as well as previous studies, we assume that normalization using a reference organ would not be affected by different respiratory motion compensation techniques [19].

Many researchers have tried to evaluate the impact of the apparent diffusion coefficient (ADC) measurements in the assessment of liver diseases. Many studies show that the cirrhotic livers are of lower ADC values than the healthy livers [20]. This is consistent with our study as we also demonstrated a linear negative correlation between liver ADC value and fibrosis stages (r = −0.63).

Table 4 ADC and nADC comparison among different fibrosis stages

| Fibrosis stage | Liver ADC p-value | nADC p-value |
|---------------|------------------|--------------|
| F0 vs F1      | 0.63836          | 0.05574      |
| F0 vs F2      | 0.5485           | 0.01287*     |
| F0 vs F3      | 0.13888          | 0.00138*     |
| F0 vs F4      | 0.02869*         | 0.00026*     |

*: significant p-value using Mann-Whitney U Test

Table 5 The optimal cut-off values of nADC liver and ADC for each fibrosis stages

| Variable        | ADC      | nADC liver |
|-----------------|----------|------------|
| F0 vs F1        | 1.55 (×10⁻³ mm²/s) | 1.44 |
| Sensitivity (%) | 70%      | 83%        |
| Specificity (%) | 66%      | 67%        |
| AUC (95% CI)    | 0.588(379 to 775) | 0.717(507 to 874) |
| F0 vs F2        | 1.53 (×10⁻³ mm²/s) | 1.41 |
| Sensitivity (%) | 72%      | 84%        |
| Specificity (%) | 55%      | 66%        |
| AUC (95% CI)    | 0.617(407 to 799) | 0.729(520-883) |
| F0 vs F3        | 1.51 (×10⁻³ mm²/s) | 1.4  |
| Sensitivity (%) | 80%      | 80%        |
| Specificity (%) | 50%      | 75%        |
| AUC (95% CI)    | 0.644(442-818)   | 0.739(565-902) |
| F0 vs F4        | 1.49 (×10⁻³ mm²/s) | 1.38 |
| Sensitivity (%) | 80%      | 90%        |
| Specificity (%) | 72%      | 80%        |
| AUC (95% CI)    | 0.648(453-812)   | 0.879(589-908) |
We also found that the mean liver ADC value in patients with hepatic fibrosis was significantly lower than that of volunteers ($1.47 \times 10^{-3} \text{mm}^2/\text{s}$ vs $1.65 \times 10^{-3} \text{mm}^2/\text{s}$, $p = 0.04$) [21, 22].

In another study done by Sandrasegaran et al. [23], ADC was able to differentiate cirrhotic from the non-cirrhotic liver with lower ADC values of the former; however, in that study, ADC could not categorize liver fibrosis in different stages; this is also confirmed by Razek et al. [24]. Earlier study done by Do et al. [25] concluded that liver ADC failed to distinguish individual stages of fibrosis, except between stages 0 and 4 mm; these results are the same to ours.

The variability in reported ADC values is further complicated using different $b$ values and acquisition methods based on breath-hold, free-breathing, or respiratory triggered techniques, which can affect ADC quantification [26, 27]. For example, in our study, mean liver ADC ($b = 800$) for the control group was $1.65 \pm 0.44 \times 10^{-3} \text{mm}^2/\text{s}$ and nADC liver $1.87 \pm 0.50$, while in a recent study done by Shin et al. [28], the mean liver ADCs for the control group ($F_0$) was $1.389 \times 10^{-3} \text{mm}^2/\text{s}$, and nADC liver was 1.977.

In the study carried out by Kim et al. [29], there was no difference between spleen ADCs values between diseased and volunteers' individuals. This supports our results as there was no significant difference between spleen ADC values among patients in comparison to control ($1 \pm 0.33 \times 10^{-3} \text{mm}^2/\text{s}$ vs $0.85 \pm 1.61 \times 10^{-3} \text{mm}^2/\text{s}$, $p = 0.24$); also, there was no significant difference in the spleen ADC between different stages of fibrosis ($r = 0.105$; $p = 0.866$).

Pervious results of Do et al. [25] showed that area under ROC curve values of nADC were higher than liver ADC values. AUC of nADC $\geq F_2$ stages was 0.864 with sensitivity and specificity of 90% and 77% respectively while ADC values were 0.655 with sensitivity and specificity of 61% and 61% respectively ($p = 0.013$); AUC of nADC $\geq F_3$ stages was 0.805 with sensitivity and specificity of 96% and 71% respectively while ADC values were 0.689 with sensitivity and specificity of 56% and 71% respectively ($p = 0.015$), and nADC AUC for F4 stage was 0.935 with sensitivity and specificity of 95% and 66% respectively while ADC AUC was 0.720 with sensitivity and specificity of 76% and 60% respectively ($p = 0.185$).

While our study reveals close results, there was a statistically significant difference between area under the receiver operating characteristic curve (AUC) of

| Liver ADC | AUC | Sensitivity | Specificity | nADC | AUC | Sensitivity | Specificity | p-value |
|----------|-----|-------------|-------------|------|-----|-------------|-------------|--------|
| ≥2       | 0.548 | 62%         | 72%         | 0.878 | 87%         | 80%         | 0.021 |
| 3-4      | 0.603 | 72%         | 72%         | 0.891 | 88.8%       | 80%         | 0.023 |
| 4        | 0.648 | 80%         | 72.2%       | 0.879 | 90%         | 80%         | 0.054 |

![Fig. 4](image) Receiver operating characteristic curves (ROC) for liver apparent diffusion coefficient (ADC; green line) and normalized liver ADC (blue line). It differentiates the patients into different fibrosis stages (A-detection of stage $\geq 2$, left curve; B-detection of stage $\geq 3$, middle curve; C-detection of cirrhosis [stage 4], right curve)
Fig. 5  a 35 years old HCV positive female patient, underwent Fibroscan with 6 kPa which was classified as F1 stage (F1=5-7 kPa). His diffusion study: reveals mildly enlarged liver with no focal lesions. The spleen was of average size with no focal lesions (a)-DWI at b = 800- and (b)-ADC map, revealed mean liver ADC = 0.95 x 10−3 mm2/s and spleen mean ADC = 0.66x 10−3 mm2/s so normalized ADC= 1.45(F1 nADC cut off = 1.44). b & c - His ultrasound study reveals (b)-mild hepatomegaly (16 cm) with no cirrhotic features or focal lesions and (c)-portal vein shows average calibre with the hepatopedal flow( numbering adjusted)

Fig. 6 a  53 years old HCV positive male patient underwent Fibroscan with 6.3kPa which was classified as F1 stage. (F1=5-7 kPa), His Diffusion study: reveals mildly enlarged liver with no focal lesions. The spleen was of average size with no focal lesions. (a)- ADC map, and (b) - DWI at b = 800- reveals liver mean ADC = 2.4 x 10−3 mm2/s and spleen mean ADC = 1.7x 10−3 mm2/s so normalized ADC= 1.429(F1 nADC cut off =1.44). b - His ultrasound study reveals mild hepatomegaly (16.5 cm) with no cirrhotic features or focal lesions. (c)- There was periportal fibrosis that can explain the low normalized ADC value as by further researches there might be subtypes in one stage
normalized liver ADC and ADC for all comparison’s subsets except for diagnosis of cirrhosis (stage 4). nADC AUC was 0.878 for detection of ≥ F2 stages with sensitivity and specificity of 87% and 80% respectively while ADC value was 0.548 with sensitivity and specificity of 62% and 72% respectively (p = 0.021); nADC AUC for ≥ F3 stages was 0.891 with sensitivity and specificity of 88.7% and 80% respectively while ADC values were 0.603 with sensitivity and specificity of 72% and 72% respectively (p = 0.023), and F4 stage nADC AUC was 0.879 with sensitivity and specificity of 90% and 80% respectively, while ADC values were 0.648 with sensitivity and specificity of 80% and 72% respectively (p = 0.054). We acknowledge some limitations in current study as small number of subjects enrolled in this study and the lack of biopsy.

**Conclusion**
Using the spleen as a reference organ to calculate the normalized liver ADC increases the diagnostic performance of liver fibrosis than using ADC alone.

**Recommendation**
- We recommend using normalized ADC as a valid non-invasive option to diagnose and stage liver fibrosis in hepatitis C patients. It can be used in obese, ascetic, or narrow intercostal space patients.
- Further studies are recommended with large participants’ number and to be correlated with liver biopsy results.
- There is a potential of subgrouping each stage using color Doppler with the DWI.

---

**Fig. 7** 45 years old HCV positive female patient, underwent Fibroscan with 14.5 kPa which was classified as F4 stage. (F4 > 12.5 kPa). His diffusion study reveals enlarged liver with cirrhotic features denoted by nodular hepatic surface, enlarged left lobe and deep fissures yet no focal lesions. The spleen was enlarged in size with no focal lesions. (a)-ADC map, and (b) - DWI at b = 800- reveals liver mean ADC = 1.6 × 10−3 mm2/s, and spleen mean ADC = 1.7× 10−3 mm2/s so normalized ADC= 0.94. (F4 nADC cut off =1.38)

**Fig. 8** Excluded case as there was moderate amount of ascites, it was classified as F4 by Fibroscan while mean liver ADC value =1.5 and mean spleen ADC=1.07 and nADC=1.4
Abbreviations
TE: Transient elastography; MR: Magnetic resonance; ADC: Apparent diffusion coefficient; nADC: Normalized apparent diffusion coefficient; PC: Personal computer (abbreviation added); DWI: Diffusion-weighted images; HCV: Hepatitis C virus; ROI: Region of interest; EPI: Echo planner imaging; AUC: Area under the curve; ROC: Receiver operating characteristic curve

Acknowledgements
Our sincere thanks to all our professors and colleagues in the Radiology Department, Faculty of Medicine, Ain Shams University.

Authors' contributions
M. M. collected, analyzed, and interpreted the patient data. O.K revised the results and was an editor in writing the manuscript. A. A. revised the results and was a major contributor in writing the manuscript. M. A. revised patients' data and was a major contributor in writing the manuscript. Q. A. referred the HCV patients to do Fibroscan examination. H. A. performed the Fibroscan examination. All authors read and approved the final manuscript.

Funding
No funds, sponsorship, or financial support to be disclosed.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Research Ethics Committee at the Faculty of Medicine, Ain Shams University, has reviewed the study protocol from ethical point of view and approves it (FMASU MD445/2017).

Consent for publication
All patients included in this research were fully conscious and older than 16 years old and gave written informed consent to participate in the study.

Consent for publication
All patients included in this research were fully conscious and older than 16 years old and gave written informed consent to publish the data contained within this study.

Competing interests
The authors declare that they have no competing interest.

Author details
1Radiology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 2Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Received: 30 March 2020 Accepted: 27 May 2020
Published online: 26 June 2020

References
1. Feier D, Balassy C, Bastai N et al (2015) The diagnostic efficacy of quantitative liver MR imaging with diffusion-weighted, SWI, and hepatospecific contrast-enhanced sequences in staging liver fibrosis—a multiparametric approach. Eur Radiol 26(2):539–546
2. Castera L (2012) Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142:1293–1302
3. Ghany MG, Nelson DR, Strader DB et al (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American association for the study of liver disease. Hepatology 54:1433–1444
4. El Refaai M (2015) Feasibility of different b-values of MRI diffusion in quantitative assessment of liver fibrosis. Journal of Cancer Prevention & Current Research 2(2):00032
5. Kovac JD, Dakovic M, Stanisavljevic D et al (2012) Diffusion-weighted MRI versus transient elastography in quantification of liver fibrosis in patients with chronic cholestatic liver diseases. Eur J Radiol 81(10):2505–2506
6. Taouli B, Chouli M, Martin AJ et al (2008) Chronic hepatitis: role of diffusion-weighted imaging and diffusion tensor imaging for the diagnosis of liver fibrosis and inflammation. J Magn Reson Imaging 28:89–95
7. Foucher J, Castera L, Bernard PH et al (2006) Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol 18: 411–412
8. Bonekamp D, Bonekamp S, Ou HY et al (2014) Assessing liver fibrosis: comparison of arterial enhancement fraction and diffusion-weighted imaging. J Magn Reson Imaging 40:1137–1146
9. Richard K, Hersh C, Ely F et al (2010) Diagnosis of liver fibrosis and cirrhosis with diffusion weighted imaging: value of normalized apparent diffusion coefficient using the spleen as reference organ. AJR 195:671–676
10. Papanikolau N, Gourtsoyianni S, Yaranmitis S et al (2010) Comparison between two-point and four-point methods for quantification of apparent diffusion coefficient of normal liver parenchyma and focal lesions: value of normalization with spleen. Eur J Radiol 73:305–309
11. Alavian SM, Mir SM, Keshvari M, Ellze PK, Behrava B, Tabatabaei SV, Lankarani KB (2009) Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thalassemia. Transfusion 49:2195–2199
12. Alavi S, Sadeghi E, Ashenagar A (2007) Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferoxamine in a patient with betathalassemia major and persistent iron overload. Blood Res 49:72–73
13. Stickland GT (2006) Liver disease in Egypt: hepatitis C suppressed schistosomiasis as a result of iatrogenic and biological factors. Hepatology 43:915–922
14. Zid M, H andra-Luca A, Kettaneh A et al (2005) Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41:48–54
15. Fraquelli M, Cassinero E, Roghi A et al (2010) Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. Am J Hematol 85: 564–568
16. Afdelh NH, Dieterich DT, Pockros PJ et al (2014) Epoetin alf a maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 126(5):1302–1311
17. Saito H, Tada S, Nakamoto N et al (2004) Efficacy of non-invasive elastometry on staging of hepatic fibrosis. Hepatol Res 29(2):97–103
18. Tosun M, Inan N, Sarisoy HT et al (2013) Diagnostic performance of conventional diffusion weighted imaging and diffusion tensor imaging for the liver fibrosis and inflammation. Eur J Radiol 82:203–207. https://doi.org/10.1016/j.ejrad.2012.09.009
19. Taouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254:47–46
20. Boulanger Y, Amara M, Lepanto L et al (2003) Diffusion-weighted MR imaging of the liver of hepatitis C patients NRW biomed, 16, pp. 132-136
21. Marcellin P, Asselah T., Boyer N (2003): Fibrosis and disease progression in chronic hepatitis C. Hepatology 38:443–449
22. Bedossa P, Dargère D, Paradis V (2003) Sampling variability of liver fibrosis in adult thalassemia patients. Eur J Radiol 43:915–922
23. Sandrasegaran K, Akisik F, Lin C et al (2009) Value of diffusionweighted MRI of the liver of hepatitis C patients NMR biomed, 16, pp. 1146–1156
24. Razek AK, Abdalla A, Omran E et al (2011) Diagnosis and quantification of hepatic fibrosis in children with diffusion weighted MR imaging. Eur J Radiol 78:129–134
25. Do RK, Chandanara H, Feller E et al (2010) Diagnosis of liver fibrosis and cirrhosis with diffusion-weighted imaging: value of normalized apparent diffusion coefficient using the spleen as reference organ. AJR 193:1556–1560
26. Azizi K, Afsari Y, Sadeghi E, Ashenagar A (2007) Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferoxamine in a patient with betathalassemia major and persistent iron overload. Blood Res 49:72–73
27. Enzinger C, Eicher C, Kovaliov D et al (2012) Diffusion-weighted imaging of the liver fibrosis and inflammation. Eur J Radiol 82:203–207
28. Shin S, Hwang H et al (2019) Liver fibrosis assessment with diffusion-weighted imaging: value of normalized apparent diffusion coefficient using the spleen as reference organ. AJR 195:671–676
29. Rasouli B, Koh DM (2010) Diffusion-weighted MR imaging of the liver. Radiology 254(1):47–66
30. Kandpal H, Sharma R, Madhusudhan KS et al (2009) Respiratorytriggered versus breath-hold diffusion- weighted MR of liver lesions: comparison of image quality and apparent diffusion coefficient values. AJR 192:915–922
31. Shin S, Hwang H et al (2019) Liver fibrosis assessment with diffusion-weighted imaging: value of liver apparent diffusion coefficient normalization using the spleen as a reference organ. Diagnostics 9(3):107
32. Kim T, Murakami T, Takahashi S et al (1999) Diffusion-weighted single-shot echoplanar MR imaging for liver disease. AJR 172:393–398

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.